News headlines about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8643823199245 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern’s rankings:
- Ritter Pharmaceuticals Inc (RTTR) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Stock market activity this week (chron.com)
- Trader’s Buzzers: Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), New York Mortgage Trust Inc. (NASDAQ:NYMT) – The Oracle Examiner (oracleexaminer.com)
- 0: Regional Health Properties, Inc., (NYSE: RHE), Ritter Pharmaceuticals, Inc., (NASDAQ: RTTR); – TNN (tradingnewsnow.com)
- A quick recap Technical data on Ritter Pharmaceuticals, Inc. (RTTR) – Wall Street Morning (wallstreetmorning.com)
Shares of Ritter Pharmaceuticals (NASDAQ RTTR) traded down $0.01 on Monday, hitting $3.07. The stock had a trading volume of 356,228 shares, compared to its average volume of 77,130. Ritter Pharmaceuticals has a 52 week low of $1.80 and a 52 week high of $20.30.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3303094/ritter-pharmaceuticals-rttr-getting-somewhat-favorable-news-coverage-analysis-shows.html.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.